Adrian Rawcliffe Net Worth & Insider Trades

Adrian Rawcliffe - Chief Executive Officer, Adaptimmune Therapeutics Plc

As of June 27, 2022

What is Adrian Rawcliffe's Net Worth?

The current estimated net worth of Adaptimmune Therapeutics Plc's Chief Executive Officer, Adrian Rawcliffe, is estimated to be about $1.37M . Adrian Rawcliffe owns about 3,290 units of Adaptimmune Therapeutics Plc common stock. In the last 6 years at Adaptimmune Therapeutics Plc, Adrian Rawcliffe has sold an estimated value of $1.35M worth.

What is Adrian Rawcliffe's Past Insider Trading?

Adrian Rawcliffe's largest sale order was 600,000 units , worth over $1.03M on March 22, 2018. In total, Adrian Rawcliffe has made about 23 transactions over 6 years of their time at Adaptimmune Therapeutics Plc. Adrian Rawcliffe usually trades in January, with the busiest year in 2022, 2020 and 2021. The most recent transaction was a sale order of 2,562 units , worth over $4.18K on June 27, 2022.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What was Adrian Rawcliffe's Salary in 2020?

As Chief Executive Officer of Adaptimmune Therapeutics Plc, Adrian Rawcliffe has a total base salary of $574,000 . Adrian Rawcliffe received compensation valued at about $2,701,602 in 2020 after becoming Chief Executive Officer. The vast majority of their compensation came in the form of option awards of $1,715,346 , other earnings, plans or compensations of $378,840 , and other compensation of $33,416 .

What is Adrian Rawcliffe's' Mailing Address?

  • Mailing address is 440 South Broad Street, Unit 1906 Philadelphia PA 19146 PA

Adaptimmune Therapeutics Plc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Adrian Rawcliffe 2020 $574,000 $1,715,346 $378,840 $33,416 $2,701,602
Adrian Rawcliffe 2019 $500,481 $1,427,399 $177,251 $49,912 $2,155,042
Adrian Rawcliffe 2018 $457,011 $730,791 $174,807 $54,775 $1,417,384
Gavin Wood 2020 $337,065 $990,268 $166,847 $73,731 $1,567,911
Helen Tayton-Martin 2020 $454,940 $857,661 $225,195 $23,531 $1,561,327
Helen Tayton-Martin 2019 $435,949 $766,900 $137,324 $30,491 $1,370,664
Helen Tayton-Martin 2018 $408,308 $730,791 $156,178 $22,007 $1,317,284
William Bertrand 2020 $443,456 $857,661 $219,511 $30,485 $1,551,113
William Bertrand 2019 $432,640 $766,900 $136,282 $35,358 $1,371,180
William Bertrand 2018 $416,000 $685,114 $159,120 $35,070 $1,295,304
John Lunger 2020 $400,000 $857,661 $198,000 $31,802 $1,487,463
John Lunger 2019 $366,867 $435,546 $94,542 $35,655 $932,610
John Lunger 2018 $316,958 $602,909 $92,948 $35,07 $1,047,885
Michael Garone 2020 $217,000 - - - $217,000
Michael Garone 2019 $206,500 - - - $206,500
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm

What are Adaptimmune Therapeutics Plc's Past Insider Trades?

Adaptimmune Therapeutics Plc's most recent insider trade came on August 1, 2022 by John Lunger who sold 2,983 units worth $5.29K . In the last 6 years, insiders at Adaptimmune Therapeutics Plc have sold an estimated value of $40.15M and bought an estimated value of $526.78M worth of shares. Insider trading is most common in January, with the busiest year in 2018. The most active traders at the company are Adrian Rawcliffe, Chief Executive Officer,  John Lunger, Chief Patient Supply Officer,  and William Charles Bertrand, Chief Operating Officer .

Adaptimmune Therapeutics PLC Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1